CR20210148A - Compuestos de isoxazol carboxamida y usos de los mismos - Google Patents

Compuestos de isoxazol carboxamida y usos de los mismos

Info

Publication number
CR20210148A
CR20210148A CR20210148A CR20210148A CR20210148A CR 20210148 A CR20210148 A CR 20210148A CR 20210148 A CR20210148 A CR 20210148A CR 20210148 A CR20210148 A CR 20210148A CR 20210148 A CR20210148 A CR 20210148A
Authority
CR
Costa Rica
Prior art keywords
carboxamide compounds
isoxazole carboxamide
sup
formula
isoxazole
Prior art date
Application number
CR20210148A
Other languages
English (en)
Inventor
Ce Wang
Hua Jiang
Rohan Eric John Beckwith
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20210148A publication Critical patent/CR20210148A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

Se proporciona un compuesto de la Fórmula (I) o una sal farmacéuticamente aceptable del mismo que ha demostrado resultar de utilidad para tratar la pérdida de la audición o un trastorno del equilibrio: Fórmula (I) en donde R<sup>1</sup> y Y están definidos en la presente.
CR20210148A 2018-09-21 2019-09-19 Compuestos de isoxazol carboxamida y usos de los mismos CR20210148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018106939 2018-09-21
PCT/IB2019/057941 WO2020058913A1 (en) 2018-09-21 2019-09-19 Isoxazole carboxamide compounds and uses thereof

Publications (1)

Publication Number Publication Date
CR20210148A true CR20210148A (es) 2021-05-18

Family

ID=68062995

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210148A CR20210148A (es) 2018-09-21 2019-09-19 Compuestos de isoxazol carboxamida y usos de los mismos

Country Status (22)

Country Link
US (1) US20210355115A1 (es)
EP (1) EP3853212A1 (es)
JP (1) JP2022501366A (es)
KR (1) KR20210066848A (es)
CN (1) CN113056455A (es)
AU (1) AU2019341709A1 (es)
BR (1) BR112021005263A2 (es)
CA (1) CA3113573A1 (es)
CL (1) CL2021000706A1 (es)
CO (1) CO2021003714A2 (es)
CR (1) CR20210148A (es)
CU (1) CU20210018A7 (es)
DO (1) DOP2021000046A (es)
EC (1) ECSP21020602A (es)
IL (1) IL281662A (es)
JO (1) JOP20210053A1 (es)
MA (1) MA53645A (es)
MX (1) MX2021003294A (es)
PE (1) PE20211071A1 (es)
PH (1) PH12021550646A1 (es)
SG (1) SG11202102847TA (es)
WO (1) WO2020058913A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240024842A (ko) * 2021-06-23 2024-02-26 에프. 호프만-라 로슈 아게 Nlrp3 억제제의 제조 공정
CN114315609B (zh) * 2022-01-15 2024-01-30 大连双硼医药化工有限公司 一种制备顺式2-氨基环己醇的工艺方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CA2568028A1 (en) 2004-05-24 2005-12-08 Auris Medical, Llc. Combined otic aspirator and medication dispenser
WO2014210159A1 (en) * 2013-06-26 2014-12-31 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
AU2015315167A1 (en) * 2014-09-10 2017-03-16 Epizyme, Inc. Isoxazole carboxamide compounds
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
US20180271837A1 (en) * 2017-03-24 2018-09-27 Novartis Ag Isoxazole carboxamide compounds and uses thereof

Also Published As

Publication number Publication date
CA3113573A1 (en) 2020-03-26
PH12021550646A1 (en) 2021-10-11
MX2021003294A (es) 2021-07-15
PE20211071A1 (es) 2021-06-09
CU20210018A7 (es) 2021-10-12
CO2021003714A2 (es) 2021-04-08
AU2019341709A1 (en) 2021-04-15
CL2021000706A1 (es) 2021-10-22
WO2020058913A1 (en) 2020-03-26
BR112021005263A2 (pt) 2021-06-15
MA53645A (fr) 2021-12-29
IL281662A (en) 2021-05-31
JP2022501366A (ja) 2022-01-06
SG11202102847TA (en) 2021-04-29
JOP20210053A1 (ar) 2021-03-21
CN113056455A (zh) 2021-06-29
US20210355115A1 (en) 2021-11-18
DOP2021000046A (es) 2021-05-31
EP3853212A1 (en) 2021-07-28
KR20210066848A (ko) 2021-06-07
ECSP21020602A (es) 2021-04-29

Similar Documents

Publication Publication Date Title
MX2023002004A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
TN2017000204A1 (en) Triazolopyrimidine compounds and uses thereof
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2021004582A (es) Compuesto 2-azabiciclo hexano inhibidor de jak.
MX2019011261A (es) Compuestos de isoxazol carboxamida y sus usos.
MX2020002825A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
MX2021006695A (es) Moduladores de trex1.
MX2017009625A (es) Compuestos macrociclicos como inhibidores de cinasas asociadas al receptor de interleucina1/4 (irak1/4) y usos de los mismos.
AU2018253590A1 (en) Imidazopyridazine compounds
AU2018274723A1 (en) Benzimidazolone derived inhibitors of BCL6
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12016500838A1 (en) Isoxazolines as therapeutic agents
PH12021550646A1 (en) Isoxazole carboxamide compounds and uses thereof
NZ746906A (en) Oxaborole esters and uses thereof
MX2020000576A (es) Compuestos quimicos.
MA39048B1 (fr) Nouveaux inhibiteurs de la dgat2
AU2019360428B2 (en) Pyrazole derivatives as H4 antagonist compounds
MX2021011286A (es) Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia.
MX2021001804A (es) Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.
MX2021004386A (es) Compuestos novedosos.
PH12020552185A1 (en) N-substituted tetrahydrothienopyridine derivatives and uses thereof
WO2018125983A8 (en) Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
MX2021007511A (es) Procedimiento para la preparacion de anilinas sustituidas.